Impact of Lung Cancer Screening With Chest Scans Combined With Coaching on Smoking Cessation in Heavy Smokers
Smoking Termination Outcomes With Pulmonary Low Dose Computed Tomography for Lung Cancer Screening (STOP-LungCancer)
Lung cancer is common and serious, but when detected early, the chances of recovery are significantly better. Tobacco use is the leading cause. To help people break free from smoking, the Fribourg Cantonal Hospital (HFR), the Center for Tobacco Prevention (CIPRET), and the Fribourg Cancer League are joining forces in the STOP-LungCancer study (Smoking Termination Outcomes with Pulmonary Low Dose Computed Tomography for Lung Cancer Screening).
What is the goal of this study? The investigators want to determine whether seeing and understanding images of the participants' own lungs helps participants quit smoking for good. Smoking cessation will be verified at 6 months using a breath test (measuring carbon monoxide), followed by a 2-year follow-up.
How does participation work? The study is open to 116 residents of the canton of Fribourg aged 50 to 79 who are heavy smokers and motivated to quit.
The program includes:
- Personalized support: 4 smoking cessation coaching sessions organized by CIPRET.
- Lung computed tomography (CT) scans: 3 exams spaced one year apart. This scan involves no needles or injections. The radiation dose is very low, about 0.6 millisieverts (mSv) per scan, and the associated risk is considered very low.
- A review of the images with a doctor: During dedicated consultations, a thoracic radiologist reviews the participant's own computed tomography (CT) scans with the participant to explain the condition of the lungs and heart.
What are the benefits? Participants receive both tailored support to quit smoking and close monitoring to detect any potential issues at a very early stage.
Studie Overzicht
Toestand
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Sandrine Foucras
- Telefoonnummer: +41 26 306 21 06
- E-mail: Sandrine.Foucras@h-fr.ch
Studie Locaties
-
-
Canton of Fribourg
-
Fribourg, Canton of Fribourg, Zwitserland, 1700
- Fribourg Cantonal Hospital (HFR)
-
Contact:
- Sandrine Foucras
- Telefoonnummer: +41 26 306 21 06
- E-mail: Sandrine.Foucras@h-fr.ch
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Residence in the canton of Fribourg
- Willingness to quit smoking
- Current smoker: > or = 20 packs years
Exclusion Criteria:
- Previous diagnosis of cancer
- Major medical problems (Eastern Cooperative Oncology Group, ECOG ≥ 2)
- Chest computed tomography (CT) scan in the last 12 months
- Hemoptysis or unintentional weight loss > 7 kilograms (kg) in the last year
- Pregnancy
- Refusal to be informed of incidental findings of medical importance
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Combined Low-Dose Computed Tomography Screening and Smoking Cessation Coaching
Single-arm experimental cohort of heavy smokers undergoing an integrated lung cancer screening and smoking cessation pathway. All enrolled participants receive the combined intervention strategy, which pairs personalized chest computed tomography (CT) imaging results with dedicated specialist counseling and structured behavioral smoking cessation support. This arm aims to evaluate how visual radiological feedback combined with tobacco cessation counseling impacts long-term smoking abstinence rates. |
Face-to-face physician consultations where a thoracic radiologist reviews the participant's own computed tomography (CT) scans with the participant to explain lung and cardiovascular health, creating a visual "teachable moment". Four structured behavioral counseling sessions delivered by certified tobacco cessation experts of the Center for Tobacco Prevention (CIPRET), personalized to support long-term abstinence.
Andere namen:
Low-dose chest computed tomography (LDCT) scans without intravenous contrast at baseline, 12 months, and 24 months, and additional follow-up LDCT when indicated by the screening result (Lung Computed Tomography Screening Reporting and Data System [Lung-RADS] category 3).
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
6-Month Smoking Abstinence Rate
Tijdsspanne: 6 months after the first chest computed tomography (CT)
|
Proportion of participants who achieve smoking abstinence at 6 months after the first chest computed tomography (CT). Abstinence is self-reported and objectively validated using exhaled carbon monoxide (CO) measurement. |
6 months after the first chest computed tomography (CT)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Smoking Abstinence Rate at 12 Months
Tijdsspanne: 12 months after the first chest computed tomography
|
Proportion of participants reporting smoking abstinence at the 12-month visit, confirmed by exhaled carbon monoxide (CO) measurement. |
12 months after the first chest computed tomography
|
|
Smoking Abstinence Rate at 24 Months
Tijdsspanne: 24 months after the first chest computed tomography
|
Proportion of participants reporting smoking abstinence at the 24-month visit, confirmed by exhaled carbon monoxide (CO) measurement. |
24 months after the first chest computed tomography
|
|
Detection Rate of Lung Nodules and Lung Cancer
Tijdsspanne: Baseline, 12 months, and 24 months
|
Proportion of participants with positive low-dose computed tomography (LDCT) findings requiring further diagnostic follow-up or tissue biopsy, categorized according to the standardized Lung Computed Tomography Screening Reporting and Data System (Lung-RADS) assessment categories. |
Baseline, 12 months, and 24 months
|
|
Prevalence of Relevant Incidental Findings on Chest Computed Tomography
Tijdsspanne: Baseline, 12 months, and 24 months
|
Proportion of relevant non-lung-nodule incidental findings detected on low-dose chest computed tomography, such as smoking-related lung disease, cardiac abnormalities and other findings unrelated to smoking. |
Baseline, 12 months, and 24 months
|
|
Factors Potentially Influencing Smoking Cessation Success
Tijdsspanne: At baseline
|
Exploratory analysis evaluating demographics such as age, sex, place of residence, socioeconomical class, and other factors such as smoking-related lung disease, and cardiac abnormalities. These analyses are exploratory in nature and are intended to generate hypotheses for future studies. No definitive causal inference will be drawn from these analyses. |
At baseline
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Philippe Khafagy, MD, Hôpital Fribourgeois
- Hoofdonderzoeker: Jon Lutz, MD, Hôpital Fribourgeois
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- BASEC-2026-01995
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Individual participant data will not be made publicly available to protect participant privacy and maintain confidentiality in accordance with Swiss regulatory requirements (Human Research Act and Federal Act on Data Protection). Aggregated data and primary results will be available in peer-reviewed scientific publications.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .